Merck & Co. Inc.MRK announced encouraging data from two pivotal phase III clinical studies for its investigational antitoxin bezlotoxumab for prevention of recurrence of Clostridium difficile (C. difficile) infection. Data from the phase III studies MODIFY I and MODIFY